Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Inv. presentation Quarterly results Director comp. Appointed COO
|
Jasper Therapeutics, Inc. (AMHCU)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/13/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
10/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
10/10/2023 |
SC 13G
| SPHERA FUNDS MANAGEMENT LTD. reports a 5.1% stake in Jasper Therapeutics, Inc. |
10/10/2023 |
8-K
| Investor presentation |
10/10/2023 |
8-K
| Regulation FD Disclosure, Financial Statements and Exhibits Interactive Data |
09/26/2023 |
4
| CROSS HERB (CFO) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 550,000 options to buy
@ $0.78, valued at
$429k
|
|
09/26/2023 |
3
| CROSS HERB (CFO) has filed a Form 3 on Jasper Therapeutics, Inc. |
08/11/2023 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
08/11/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/11/2023 |
8-K
| Quarterly results |
06/08/2023 |
4
| Kapoor Vishal (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
4
| Klein Lawrence Otto (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
4
| EMSTER KURT VON (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
4
| Shizuru Judith Anne (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
4
| Nolet Chris (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
4
| Lis William (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
4
| French Anna Louise (Director) has filed a Form 4 on Jasper Therapeutics, Inc.
Txns:
| Granted 47,000 options to buy
@ $1.6, valued at
$75.2k
|
|
06/08/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
06/02/2023 |
8-K
| Investor presentation |
05/08/2023 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
05/05/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
04/21/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/21/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/21/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/14/2023 |
144
| Form 144 - Report of proposed sale of securities: |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
04/14/2023 |
8-K
| Quarterly results |
04/13/2023 |
144
| Form 144 - Report of proposed sale of securities: |
|
|
|